Remedy Health buys HealthCentral, promises broader ad reach

Share this article:

Health information site HealthCentral has been acquired by Remedy Health, a multimedia provider of content and tools designed to help people manage disease, the firms said today.

Terms of the deal, expected to close this week, were not disclosed by the companies, both of which are owned by private investors.

HealthCentral's network of bloggers and expert patients in a variety of topic areas supplements the digital side of the Remedy media portfolio, which spans mobile, print and point-of-care information and technology products.

“With the acquisition of HealthCentral, we've dramatically increased our online reach, sales capacity and our ability to create industry leading health information and technology applications,” stated Mike Cunnion, CEO of Remedy. “The combination creates exciting opportunities to provide even more value to our audiences, customers and strategic partners.”

The new company said its reach now includes 23 million unique monthly visitors to its health websites—the combined total of the two firms' online health properties.

In October, HealthCentral drew only 3.2 million unique visitors, according to data from comScore. Remedy's online traffic figures were not immediately available.

Remedy already reaches more than 17 million patients and caregivers at pharmacy counters nationwide through magazines and newsletters, has a 20-million member customer database, and keeps a network of more than 600,000 physicians, it said.

HealthCentral CEO Chris Schroeder will remain involved in the business as a consultant to Remedy and the board of directors, and has been named an advisor to Polaris Ventures, one of a number of HealthCentral investors. Remedy is owned by private investment firm Veronis Suhler Stevenson (VSS).

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...